Cleveland BioLabs, Inc. has changed its operational focus as a result of its maturing development pipeline and a reduced need for lab and preclinical services. The company has transferred its lab and preclinical services personnel to Buffalo BioLabs, LLC, an entity affiliated with one of the company's co-founders, Andrei Gudkov, Ph.D., D. Sci. Cleveland BioLabs has executed a service agreement for continued access to this team on an as-needed basis.
"As we noted on our second quarter call, our maturing product pipeline requires less laboratory and preclinical support. We believe this restructuring allows us to sharpen our clinical development focus and preserve financial resources, while maintaining priority access to existing laboratory and preclinical services talent," said Yakov Kogan, Ph.D., chief executive officer of Cleveland BioLabs.